CN102791283A - 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用 - Google Patents

转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用 Download PDF

Info

Publication number
CN102791283A
CN102791283A CN2011800104876A CN201180010487A CN102791283A CN 102791283 A CN102791283 A CN 102791283A CN 2011800104876 A CN2011800104876 A CN 2011800104876A CN 201180010487 A CN201180010487 A CN 201180010487A CN 102791283 A CN102791283 A CN 102791283A
Authority
CN
China
Prior art keywords
seq
tgf
peptide
polynucleotide
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800104876A
Other languages
English (en)
Chinese (zh)
Inventor
哈维尔·多特德拉斯埃雷里亚斯
米格尔何塞·马尔多纳多洛佩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Digna Biotech SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Digna Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL, Digna Biotech SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of CN102791283A publication Critical patent/CN102791283A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800104876A 2010-02-22 2011-02-21 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用 Pending CN102791283A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/709,895 2010-02-22
US12/709,895 US8158589B2 (en) 2003-08-22 2010-02-22 Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
PCT/EP2011/052543 WO2011101478A1 (en) 2010-02-22 2011-02-21 USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-β1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE

Publications (1)

Publication Number Publication Date
CN102791283A true CN102791283A (zh) 2012-11-21

Family

ID=43757920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800104876A Pending CN102791283A (zh) 2010-02-22 2011-02-21 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用

Country Status (10)

Country Link
US (2) US8158589B2 (https=)
EP (1) EP2538962A1 (https=)
JP (1) JP2013520405A (https=)
CN (1) CN102791283A (https=)
AU (1) AU2011217181A1 (https=)
BR (1) BR112012020953A2 (https=)
CA (1) CA2790625A1 (https=)
MX (1) MX2012009748A (https=)
RU (1) RU2012140704A (https=)
WO (1) WO2011101478A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862434A (zh) * 2019-10-28 2020-03-06 中山大学 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用
WO2021037290A3 (zh) * 2019-08-27 2021-04-15 南京安吉生物科技有限公司 一种融合多肽及其应用
CN113966342A (zh) * 2019-06-05 2022-01-21 Io生物技术公司 TGF-β疫苗

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
ES2423382B1 (es) * 2012-02-16 2014-07-15 Consejo Superior De Investigaciones Científicas (Csic) Inhibidor de la produccion de endoglina soluble y su aplicacion en patologias donde la endoglina soluble tiene un efecto patogenico
WO2013148155A1 (en) * 2012-03-26 2013-10-03 Digna Biotech Usa, Llc Compositions and methods for the treatment of dry eye disease
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
RU2016106641A (ru) * 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
CA2927898C (en) * 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2015072580A1 (ja) 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
EP3125907A4 (en) 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
ES2965877T3 (es) * 2015-10-27 2024-04-17 Univ Taipei Medical Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas
JPWO2017110093A1 (ja) 2015-12-24 2018-10-11 学校法人同志社 ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
RU2700941C1 (ru) * 2019-07-05 2019-09-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ предупреждения развития помутнения роговицы при ее механических травмах
RU2701178C1 (ru) * 2019-07-10 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ ускорения заживления роговицы при ее механических травмах
JP2020073483A (ja) * 2019-10-30 2020-05-14 京都府公立大学法人 角膜内皮ｅｃｍ治療薬
EP4269429A4 (en) * 2020-12-23 2025-07-30 Korea Inst Sci & Tech NEW PEPTIDE CAPABLE OF INHIBITING TGF-BETA SIGNALING AND ITS UTILIZATION
CN115040535B (zh) * 2022-08-15 2022-12-16 华南理工大学 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用
WO2026027520A1 (en) 2024-07-30 2026-02-05 Disit Biotech, S.L. Method of preparing parenteral formulations and formulations prepared therefrom

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1669367A1 (en) * 2003-08-22 2006-06-14 Proyecto de Biomedicina Cima, S.L. Peptides which can bind to transforming growth factor beta 1 (tgf-beta1)
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
AU5593398A (en) * 1996-12-05 1998-06-29 Alcon Laboratories, Inc. The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2000037072A1 (en) 1998-12-22 2000-06-29 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
AU1533402A (en) 2000-10-13 2002-04-22 Univ Johns Hopkins Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
EP1974740A4 (en) * 2005-10-24 2010-09-01 Proyecto Biomedicina Cima Sl USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1669367A1 (en) * 2003-08-22 2006-06-14 Proyecto de Biomedicina Cima, S.L. Peptides which can bind to transforming growth factor beta 1 (tgf-beta1)
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113966342A (zh) * 2019-06-05 2022-01-21 Io生物技术公司 TGF-β疫苗
WO2021037290A3 (zh) * 2019-08-27 2021-04-15 南京安吉生物科技有限公司 一种融合多肽及其应用
GB2600594A (en) * 2019-08-27 2022-05-04 Nanjing Anji Biological Tech Co Ltd Fused polypeptide and use thereof
CN110862434A (zh) * 2019-10-28 2020-03-06 中山大学 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用
CN110862434B (zh) * 2019-10-28 2021-07-06 中山大学 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用

Also Published As

Publication number Publication date
AU2011217181A1 (en) 2012-09-06
CA2790625A1 (en) 2011-08-25
RU2012140704A (ru) 2014-03-27
US20120315256A1 (en) 2012-12-13
US20100222280A1 (en) 2010-09-02
JP2013520405A (ja) 2013-06-06
EP2538962A1 (en) 2013-01-02
US8158589B2 (en) 2012-04-17
BR112012020953A2 (pt) 2017-02-07
WO2011101478A1 (en) 2011-08-25
MX2012009748A (es) 2012-12-05

Similar Documents

Publication Publication Date Title
CN102791283A (zh) 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用
JP4361734B2 (ja) 血管形成の調節に有用なトリプトファニル−ｔＲＮＡシンテターゼ由来ポリペプチド
CN109535243B (zh) 人肝细胞生长因子突变体及其应用
JP2002507546A (ja) 角質細胞増殖因子−２の治療的使用
AU2016320905A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
WO2013005603A1 (ja) 結膜におけるアレルギー性炎症の予防及び／又は治療剤
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
CN102336812B (zh) 一种具有抑制血管生成活性的多肽
CN101503458B (zh) 预防和治疗血管新生的小分子多肽及其应用
CN105017406B (zh) 一类新的具有神经保护功能的多肽
EP4574211A2 (en) Compositions of growth factor for the treatment of eye disease
CA3147828C (en) Agent for use in treatment or prevention of ophthalmic disorders
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
WO2022204331A1 (en) Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
CN109970847B (zh) 一类新的抑制新生血管的多肽及其应用
HK40128523A (en) Compositions of growth factor for the treatment of eye disease
JP2019523234A (ja) 眼疾患の処置
CN116966272A (zh) 一种sgp130蛋白在制备治疗角膜炎症及角膜炎适应症产品中的应用
HK40072504A (en) Agent for use in treatment or prevention of ophthalmic disorders
HK1118017A (en) THE USE OF THYMOSIN β4, ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE
HK1074577B (en) THE USE OF THYMOSIN β4 (Tβ4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING DISORDERS OF EYE AND THE SURROUNDING TISSUE

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20121121

C20 Patent right or utility model deemed to be abandoned or is abandoned